


Intraperitoneal chemo offers lasting benefit in ovarian cancer

March 27 2015



(HealthDay)—Intraperitoneal (IP) chemotherapy offers lasting benefit for patients with advanced ovarian cancer, according to a study published online March 23 in the *Journal of Clinical Oncology*.

Devansu Tewari, M.D., from the Kaiser Permanente Irvine Medical Center in California, and colleagues examined long-term survival after IP [chemotherapy](#) in patients with advanced [ovarian cancer](#). Data were analyzed for 876 patients from Gynecologic Oncology Group protocols 114 and 172, followed for a median of 10.7 years.

The researchers found that median survival was 61.8 months with IP therapy, compared with 51.4 months for intravenous therapy. IP therapy correlated with a reduced risk of death (adjusted hazard ratio [aHR], 0.77; $P = 0.002$). Among those with gross residual (≤ 1 cm) disease, IP therapy improved survival (aHR, 0.75 $P = 0.006$). For each IP

chemotherapy cycle completed, the risk of death decreased by 12 percent (aHR, 0.88; P survival (all P patients; with each year of age there was a 5 percent decrease in probability of completion (odds ratio, 0.95; P

"The advantage of IP over intravenous chemotherapy extends beyond 10 years," the authors write. "Survival improved with increasing number of IP cycles."

One author disclosed financial ties to the pharmaceutical industry.

More information: [Abstract](#)

[Full Text \(subscription or payment may be required\)](#)

[Full Text](#)

Copyright © 2015 [HealthDay](#). All rights reserved.

Citation: Intraperitoneal chemo offers lasting benefit in ovarian cancer (2015, March 27) retrieved 14 May 2024 from <https://medicalxpress.com/news/2015-03-intraperitoneal-chemo-benefit-ovarian-cancer.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--